Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA® (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer

Oncologie is collaborating with MSD in this clinical study to evaluate the combination of bavituximab and KEYTRUDA in patients with advanced gastric or gastroesophageal cancer.